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ABSTRACT

The goal of this project was to study the effect of the presence or absence of the cofactor
NADPH on the binding and release of ligand methotrexate (MTX) to/from Bacillus
stearothermophilus (Bs) dihydrofolate reductase (DHFR). A previously developed,
fluorescently-labeled Bs DHFR (C73A/S131CMDCC DHFR) was used to investigate the
kinetics and protein conformational motions associated with the binding of NADPH and
the binding of methotrexate to the holoenzyme. This Bs DHFR contains a distal cysteine
where

the

fluorophore,

N-[2-(1-maleimidyl)ethyl]-7-(diethylamino)coumarin-3-

carboxamide (MDCC) can be covalently attached. This probe is sensitive to the local
molecular environment, reporting on changes in the protein conformation associated with
ligand binding. Intrinsic tryptophan fluorescence of the unlabeled Bs DHFR construct
(C73A/S131C DHFR) was also used to detect changes in conformational motion upon
ligand and cofactor association and dissociation.
Previous stopped-flow data indicates the presence of two native state Bs DHFR
conformers that bind to ligand at different rates. Similarly, two conformations of
Escherichia coli DHFR in unbound state were reported. Intrinsic tryptophan fluorescence
of C73A/S131C Bs DHFR and probe fluorescence of C73A/S131CMDCC Bs DHFR
both report on ligand binding. The labeled and unlabeled DHFRs report on the two
different conformers, respectively. This study shows that NADPH binding significantly
slows down the dissociation rate (approx. 1000-fold) of methotrexate from Bs DHFR
from 0.015 ±0.007965 s-1 to 0.000021 ±0.00000271 s-1. This demonstrates the importance
of NAHPH in the analysis and study of DHFR.
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Introduction:
Dihydrofolate reductase (DHFR) is an essential enzyme found in nearly all life
forms. DHFR catalyzes the formation of tetrahydrofolate from dihydrofolate using the
cofactor NADPH as the reducing agent. Tetrahydrofolate is required in the synthesis of
purines, thymidylate and several amino acids and reducing its activity prevents cells from
growing or multiplying. This makes DHFR an important pharmaceutical target for
development of antibiotics and pharmaceuticals targeting cancer [ 41, 42 ].
Pharmaceuticals that inhibit DHFR’s function are known as antifolates [ 19 ]. Studying
how these drugs interact with DHFR is important for further research into protein
dynamics and the design of new pharmaceuticals.
DHFR has become one of the main model systems for studying protein
conformational motions [ 10 ]. Enzymes are thought to exist in a variety of conformations
that are in equilibrium with each other. For many enzymes, one conformer is the stable
state; for others, more than one stable conformer exists in equilibrium [ 13, 27 ]. An
enzyme that exists in multiple stable conformers has the possibility of more elaborate
regulation. Studies on how one conformer as opposed to the other binds ligands leads to a
better understanding of potential regulation [ 1, 8, 9, 24 ].
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Figure 1: A visualization of how enzyme conformers exist in many conformations with a
prominent few conformations that are most stable.
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DHFR

Figure 2: The reaction of Dihydrofolate to Tetrahydrofolate by Dihydrofolate Reductase
using NADPH as a cofactor.
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Previous published work on DHFR has demonstrated at least two stable
conformations that bind ligands at different rates [ 30 ]. A confounding factor of this
system is the cofactor NADPH. Most research has focused on the apoenzyme (enzyme
without cofactor bound), presumably to avoid the complexity of the bound cofactor. As a
result, less is known about the binding of methotrexate (MTX) to the holoenzyme
(enzyme with cofactor bound). However, the holoenzyme needs to be studied because it
is the biologically relevant species. Understanding the interactions between DHFR,
NADPH, and methotrexate will increase the understanding of structure function
relationships in DHFR. Thus, the goal is to determine the extent to which NADPH
impacts the binding of DHFR to methotrexate and the associated conformational
dynamics. There are three specific goals:
•

Find rates of binding and dissociation and associated conformational
changes of methotrexate binding to Bs DHFR.

•

Determine the rates of binding and dissociation of NADPH to/from Bs
DHFR and rates of associated conformational changes.

•

Determine the rate of methotrexate binding to the Bs DHFR holoenzyme
(with NADPH bound), rate of release of methotrexate from holoenzyme,
and rates of associated conformational changes.

Stopped-flow fluorescence spectroscopy was used to determine rates of binding,
dissociation and associated conformational changes. This method measures changes in
fluorescence intensity over time after two fluid flows are mixed together. The
measurement begins as the flows are stopped.

The dead time of the instrument is

approximately one to two milliseconds. In this project, I measured changes in the
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intensity of the intrinsic tryptophan fluorescence for the unlabeled enzyme. I measured
changes in the fluorescence intensity of the covalently bound fluorophore MDCC for the
labeled enzyme. In both measurements, the intensity of the fluorophore signal will
change when the conformation of the Bs DHFR changes. This is because the environment
of the fluorophore changes when the protein undergoes a conformational change.
Integrating these two fluorescence signals allowed me to differentiate between
binding events associated with each conformer. Each of the two conformers may have
different biding mechanisms to methotrexate. For example, one conformer may bind
faster than the other or release methotrexate more rapidly. There may also be
conformational changes that are associated with the methotrexate binding event or ones
that follow the binding event for one or both conformers. At low methotrexate
concentrations, concentration dependent binding steps can be seen the best. At higher
methotrexate concentrations, the concentration dependent binding steps are so fast they
are over in the dead time of the instrument, allowing the slower concentration
independent conformational changes to be measured clearly. With these tools, we
determined the rates of binding events and conformational changes for the binding of
NADPH and methotrexate to both the apoenzyme, the enzyme without its cofactor
NADPH, and the holoenzyme, the enzyme with the cofactor NADPH bound.

4

Figure 3: A graphical representation of the structure of Bs DHFR (PDB ID: 1ZDR) [ 1 ].
These models show the front (top) where the MTX binding site is located and the back
(bottom) where the MDCC fluorescent probe gets attached. Residue 131, the site of
labeling, is shown as a magenta sphere.

Material and methods
Protein expression and purification
An E. coli BL21 cell line transformed with C73A S131C Bs DHFR with the was
obtained from a previous study done by Maryam Alapa [ 1 ]. The unlabeled Bs DHFR
construct (C73A/S131C Bs DHFR) was grown and expressed in LB broth containing 100
μg/mL ampicillin at 37 °C. OD600 was allowed to reach 0.6; expression was then induced
using 1 mM isopropyl-β-D-thiogalactopyranoside (IPTG) and the cells expressed
overnight at 30 °C. Cells were washed in 0.9% NaCl and pelleted.
5

37˚C

LB Broth + 100 µg Ampicillin + Cells

30˚C

At OD600=0.6 Induced
with IPTG

Use centrifuge to
pellet cells

Centrifuge

Dissolve + sonicate cell pellet

Run supernatant through anion
exchange column

Use centrifugal filter tubes
to wash and concentrate

Figure 4: Process figure for the growth and purification of C73A S131C Bs DHFR.

The cells were suspended in 40 mM N-2-hydroxyethylpiperazine-N’-2-ethanelsulfonic
acid (HEPES) buffer at pH 6.8, then lysed by sonication at 10% duty with an output of 5
pulsed for 4 minutes. The supernatant was loaded onto an SP-sepharose C-25 column and
eluted with 0.2 M NaCl in 40 mM HEPES (pH 6.8). The Bs DHFR fractions were
collected, exchanged into 40 mM HEPES (pH 6.8), concentrated, and stored at -80 °C
with a typical yield of 2.5 mg of protein for 1 L of Expressed protein broth. The purity
was verified by SDS-PAGE electrophoresis.
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Figure 5: This is a typical gel for the purification of C73A/S131C Bs DHFR using a SPsepharose C-25 column. The molecular weight of Bs DHFR is 18.6 kDa A) lysate, B)
flow column 1, C) flow column 2, D) eluted DHFR 1, E) eluted DHFR 2, F) concentrated
DHFR (approximately 0.002 mg) at very high purity.

Preparation of C73A/S131CMDCC Bs DHFR
Covalent attachment of the MDCC fluorophore to cysteine on the Bs DHFR
complex at position 131 was initiated by adding a 3-fold molar excess of 0.22 mM stock
solution of MDCC fluorophore (ThermoFisher Scientific, Catalog number: D10253,
7-Diethylamino-3-((((2-Maleimidyl)ethyl)amino)carbonyl)coumarin, MW 383.4 g/mol),
dissolved in dimethyl sulfoxide, to purified C73A/S131C Bs DHFR in pH 7.2 HEPES
buffer. The final concentrations were 139.1 μM of MDCC and 41.5 μM of Bs DHFR with
7

a final volume of 1.65 mL. The mixture was covered with aluminum foil to protect the
sample from light and incubated at room temperature for 2 h. The sample was dialyzed
twice, once for 4 h at 4 °C and once overnight at 4 °C in HEPES pH 6.8 to remove excess
dye and to exchange buffer. The extinction coefficient of DHFR (25,565 M−1cm−1 at 280
nm) and of MDCC (10,000 M−1cm−1 at 280 nm and 50,000 M−1cm−1 at 419 nm) were
used to calculate labeling efficiency. Labeling efficiency was found to be ~99.4 % from
absorbance measurements at 280 and 419 nm using a Thermo Scientific NanoDrop 2000c
UV-Vis spectrophotometer.

Absorption = Extinction coefficient * Concentration * Distance
(M -1 cm -1)
(M)
(cm)
A280 DHFR
25565
0.1
A280 MDCC
10000
0.1
A419 MDCC
50000
0.1
Figure 6: This shows the equation and constants used in the calculation of enzyme
concentration, amount of MDCC needed for the labeling, and the labeling efficiency.
Labeling efficiency is calculated by comparing the concentration calculation of MDCC at
419 nm to the concentration calculation of DHFR at 280nm (subtracting out the A280 of
MDCC from the total). Sample calculation Fig. 19 in Appendix.

Unlabeled apoenzyme Bs DHFR mixed with methotrexate
Methotrexate (2–200 µM) was mixed with 2 µM of C73A/S131C Bs DHFR in 50
mM 2-(N-morpholino) ethanesulfonic acid, 25 mM tris(hydroxymethyl)-aminomethane,
25 mM ethanolamine, and 100 mM NaCl (MTEN buffer) at pH 7 in an Applied
Photophysics SX20 stopped-flow apparatus. The changes in fluorescence emission
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intensity for C73A/S131C Bs DHFR (excitation at 290 nm, emission with a 320 nm
cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25 –
500 s. Five individual traces were used to obtain an average trace for each condition.
Control data for responses were obtained by taking fluorescence readings of each
component when separately when combined in the stopped-flow apparatus with buffer.
For example, to determine the contribution of DHFR to the fluorescence of the
DHFR/MTX experiment, DHFR was mixed in the stopped-flow cell with buffer and the
fluorescence measured.
To measure the dissociation rate of the DHFR-MTX complex, 2 μM enzyme was
incubated with 10 μM methotrexate in MTEN buffer at pH 7. The enzyme-methotrexate
solution was then mixed in a stopped-flow apparatus with 300 μM or 700 μM
trimethoprim (TMP) which displaces methotrexate in the active site. The dissociation
event was monitored by following the fluorescence emission changes at 320 nm for 500s.
To further explore the dissociation rate of the DHFR-MTX complex a
concentration of 1 μM enzyme, 5 μM methotrexate, and 700 μM trimethoprim (TMP) in
MTEN buffer at pH 7 was mixed (TMP mixed in immediately prior to fluorescence
readings) and placed in a Flouromax SX20 spectrophotometer. The dissociation event
was monitored by following the fluorescence emission changes at 320 nm for 600s and
172800s (48h).

Labeled apoenzyme Bs DHFR mixed with methotrexate
Methotrexate (2– 200 µM) was mixed with 2 µM of C73A/S131CMDCC Bs DHFR
in MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence

9

emission intensity for C73A/S131CMDCC (excitation at 419 nm, emission with a 450 nm
cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25500s. Five individual traces were used to obtain an average trace for each condition.
Control data for responses were obtained by taking fluorescence readings of each
component separately when combined in the stopped-flow apparatus with buffer.
To measure the dissociation rate of the DHFR-MTX complex, 2 μM enzyme was
incubated with 10 μM methotrexate in MTEN buffer at pH 7. The enzyme-methotrexate
solution was then mixed in a stopped-flow apparatus with 300 μM or 700 μM TMP to
displace methotrexate. The dissociation event was monitored by following the
fluorescence emission changes at 450 nm for 500s.
To further explore the dissociation rate of the DHFR-MTX complex a
concentration of 1 μM enzyme, 5 μM methotrexate, and 700 μM trimethoprim (TMP) in
MTEN buffer at pH 7 was mixed (TMP mixed in immediately prior to fluorescence
readings) and placed in a Flouromax SX20 spectrophotometer. The dissociation event
was monitored by following the fluorescence emission changes at 450 nm for 600s and
172800s (48h)

Unlabeled apoenzyme Bs DHFR mixed with NADPH
NADPH (2–200 µM) was mixed with 2 µM of C73A/S131C Bs DHFR in MTEN
buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence emission
intensity for C73A/S131C Bs DHFR (excitation at 290 nm, emission with a 320 nm
cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25500s. Five individual traces were used to obtain an average trace for each condition.

10

Control data for responses were obtained by taking fluorescence readings of each
component separately when combined in the stopped-flow apparatus with buffer.

Labeled apoenzyme Bs DHFR mixed with NADPH
NADPH (2– 200 µM) was mixed with 2 µM of C73A/S131CMDCC Bs DHFR in
MTEN buffer at pH 7 in the stopped-flow apparatus. The changes in fluorescence
emission intensity for C73A/S131CMDCC (excitation at 419 nm emission with a 450 nm
cutoff filter) were recorded in the stopped-flow apparatus (slit widths 1 mm) for 0.25500s. Five individual traces were used to obtain an average trace for each condition.
Control data for responses were obtained by taking fluorescence readings of each
component separately when combined in the stopped-flow apparatus with buffer.

Unlabeled holoenzyme Bs DHFR mixed with methotrexate
Methotrexate (2– 200 µM) was mixed with 2 µM of C73A/S131C Bs DHFR, preincubated with 10 µM NADPH, in MTEN buffer at pH 7 in the stopped-flow apparatus.
The changes in fluorescence emission intensity for C73A/S131C Bs DHFR (excitation at
290 nm, emission with a 320 nm cutoff filter) were recorded in the stopped-flow
apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an
average trace for each condition. Control data for responses were obtained by taking
fluorescence readings of each component separately when combined in the stopped-flow
apparatus with buffer.
To measure the dissociation rate of the DHFR-NADPH-MTX complex, 2 μM
enzyme incubated with 10 μM NADPH was incubated with 10 μM methotrexate in
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MTEN buffer at pH 7. The enzyme-methotrexate solution was then mixed in a stoppedflow apparatus with 300 μM or 700 μM TMP to displace methotrexate. The dissociation
event was monitored by following the fluorescence emission changes at 320nm for 500s.
To further explore the dissociation rate of the DHFR-NADPH-MTX complex a
concentration of 1 μM enzyme, 5 μM NADPH, 5 μM methotrexate, and 700 μM
trimethoprim (TMP) in MTEN buffer at pH 7 was mixed (TMP mixed in immediately
prior to fluorescence readings) and placed in a Flouromax SX20 spectrophotometer. The
dissociation event was monitored by following the fluorescence emission changes at 320
nm for 600s and 172800s (48h)

Labeled holoenzyme Bs DHFR mixed with methotrexate
Methotrexate (2– 200 µM) was mixed with 2 µM of C73A/S131CMDCC Bs DHFR
pre-incubated with 10 µM NADPH in MTEN buffer at pH 7 in the stopped-flow
apparatus. The changes in fluorescence emission intensity C73A/S131CMDCC (excitation
at 419 nm, emission with a 450 nm cutoff filter) were recorded in the stopped-flow
apparatus (slit widths 1 mm) for 0.25-500s. Five individual traces were used to obtain an
average trace for each condition. Control data for responses were obtained by taking
fluorescence readings of each component separately when combined in the stopped-flow
apparatus with buffer.
To measure the dissociation rate of the DHFR-NADPH-MTX complex, 2 μM
enzyme incubated with 10 μM NADPH was incubated with 10 μM methotrexate in
MTEN buffer at pH 7. The enzyme-methotrexate solution was then mixed in a stopped-
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flow apparatus with 300 μM or 700 μM TMP to displace methotrexate. The dissociation
event was monitored by following the fluorescence emission changes at 450 nm for 500s.
To further explore the dissociation rate of the DHFR-NADPH-MTX complex a
concentration of 1 μM enzyme, 5 μM NADPH, 5 μM methotrexate, and 700 μM
trimethoprim (TMP) in MTEN buffer at pH 7 was mixed (TMP mixed in immediately
prior to fluorescence readings) and placed in a Flouromax SX20 spectrophotometer. The
dissociation event was monitored by following the fluorescence emission changes at 450
nm for 600s and 172800s (48h)

Data Analysis
Data Analysis was done using Dynafit 4 [ 23 ], a minimization fitting program, to
do an optimization analysis to fit the data to the following kinetic model. The model for
the binding of methotrexate to Bs DHFR elucidated by previous studies (Fig. 4) was used
as a basis for the Dynafit analysis. For each section of the model, only one, two steps, or
pure conformational change step (E+LE.L, or E’+LE’.LE.L or E’.L
E.L) were used with the goal of using as few steps as possible to adequately explain
each set of the data. Each trace typically shows evidence of only one or two steps with all
timescales and wavelength showing the whole picture. Dynafit files and scripts are found
in each respective binding folder under the file heading: Dynafit Ready Data Files +
Scripts. Binding (k1) steps were all successfully fit to a one step model and all
conformational change (k2) steps were fit to a simple conformational change step as well
as a two step model.
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-1 -1

k1= 23μM s
E + MTX

EMTX

-1

k3

k-3

k-1= 0.02s
-1
k2= 1.7s

k-2

-1 -1

E’ + MTX

k4= 0.067μM s
k-4 =0.02s

E’MTX

-1

Figure 7: The minimal model for methotrexate binding to Bs DHFR. E and E’ represent
different conformational states of Bs DHFR, L represents a ligand (Methotrexate or
NADPH in this case), and E.L and E’.L represent different conformational states of Bs
DHFR bound to a ligand. The rate constants are first order rate constants in units of s-1 for
the conformational changes and second order rate constant μM- 1 s-1 for the ligand binding
steps.
Analysis for the data was carried out through an iterative process. Initial estimates
for parameters such as enzyme, buffer, and ligand responses (Table 1) were determined
from control data. Responses were determined by subtracting out the background
fluorescence and dividing by concentration. The control parameters were constantly
monitored to prevent significant deviation from measured values. These parameters
included the response values for the enzyme alone, the response values for the ligand
alone, and the offset which corresponds to the response generated by the buffer alone.
Based on rough single exponential analysis of the emission vs. time curves, using
multiple concentrations of methotrexate and NADPH mixed with the enzyme, initial
parameter estimates for k1 along with the rough values for the known responses were
used to get an initial calculation for the concentration of enzyme (Fig. 8).
14

Figure 8: Initial estimates for binding constants. The estimate of the binding constant is
indicated by the slope of a best fit linear line through the data (red box). Only the
approximation of L MTX W.NADPH was quite far off in terms of precision. This data as
well as the calculation of the kObs values for each concentration can be found in Folder:
kObs graphs and data, within each of the corresponding binding folders.
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This concentration reflects the percent of the enzyme that is in the E conformation
for binding NADPH through the E+LEL pathway. This is important for knowing the
distribution between E and E’ while the total enzyme concentration is known to be 1 μM.
With nearly all parameters decently defined, each trace was run through an iterative
process where the parameters were allowed to vary individually and in groups as well as
all at once to develop a best fit trace for each fitting. The values from these were then
used to determine global best fits across data sets.

DHFR
NADPH
DHFR.NADPH
DHFR'.NADPH

DHFR
MTX
DHFR.MTX
DHFR'.MTX

NADPH
Binding
L
U
1.92
0.477
0.000001
0.0352
0.965
0.961
0.942
0.94
MTX
Binding
L
U
1.935
0.86 DHFR.NADPH
0.00001
0.001 MTX
0.934
0.756 DHFR.NADPH.MTX
0.746
0.73 DHFR'.NADPH.MTX

MTX
Binding
L
U
5.21
0.89
0.00001
0.001
5.1
0.856
5.1
0.83

Table 1: Control values for the Dynafit response constants. Used as initial values and
refined through the Dynafit iterative modeling process. File: Response Values.

Results and Discussion
Methotrexate Mixed with Bs DHFR
Independently confirming the model of methotrexate binding and the rates at
which methotrexate binds to Bs DHFR is important for further analysis. Knowing the
rates of binding and conformational changes and how they are different for the
16

DHFR.NADPH system is important for determining NADPH’s role in methotrexate
binding. Seeing the same previously observed conformational changes researched by
Maryam Alapa would ideally confirm the conformational equilibrium in Bs DHFR [ 1 ].
The binding of methotrexate to unlabeled Bs DHFR causes a change in tryptophan
fluorescence (290 nm) intensity. There are three tryptophan molecules (Trp22, Trp85 and
Trp135) in our Bs DHFR enzyme, one of which is in the active site. These tryptophan
molecules give off varying amounts of fluorescence depending on their local
environment. For instance, one can clearly detect change in the fluorescence intensity
when a molecule is binding to the active site and detect changes in fluorescence intensity
as the protein shifts conformation [ 1 ] .
The binding of methotrexate to unlabeled Bs DHFR causes a fast methotrexate
concentration dependent decrease in tryptophan (290) fluorescence intensity. There is
also a second, slower decrease in fluorescence, the rate of which does not vary with
methotrexate concentration. The traces were fitted to a two-step equation. The fast
concentration dependent decrease is over within 0.25 seconds and has a k1 of 23.8 ±2.2
μM- 1s-1 and k-1 was calculated to be 0.8 ±0.29 s-1. (Table 2) The fast step is attributed to
methotrexate binding, k1, and the slower step is attributed to the conformational change,
k2, as the DHFR-MTX complex moves to equilibrium between its two forms. The rate
constant k2 was found to be 0.02 ±0.0027 s-1. (Table 2) It was not possible to determine k2

from this particular data.
The binding of methotrexate to labeled Bs DHFR causes a slower concentration

dependent decrease in MDCC fluorescence (419 nm) intensity. The MDCC probe which
is attached to the Bs DHFR at a distal site is sensitive to small changes in its local
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environment changing fluorescence intensity as any binding or conformational changes
occur. The traces were fitted to a two-step equation. This is a concentration dependent
decrease is over within 100 seconds and has a k4 of 0.072 ±00013 μM- 1s-1 and a k-4 of
approximately 0.0064 ±0.000066 s-1. (Table 2)
Longer unlabeled traces showed a slow decrease in fluorescence intensity
indicating a slow methotrexate concentration independent decrease. By running these
samples at high methotrexate concentrations, the methotrexate concentration dependent
step becomes so fast that it cannot be observed on the timescale of our data collection and
all that can be seen is the concentration independent step. These longer traces were fit to
a two-step model. The fast step is attributed to methotrexate binding (k1), and the slower
step is attributed to the conformational change (k2) as the DHFR-MTX complex shifts its
conformation finding a new conformation equilibrium with different amounts of DHFR
being in each conformation. The rate constant k2 was fond to be 0.02 ±0.0027 s-1 and k-2
could not be calculated from the data. (Table 2)
-1 -1

k1= 23.8μM s
E + MTX

EMTX

-1

k3

k-3

k-1= 0.08s
k2=0.02s-1

k-2=N/A

-1 -1

E’ + MTX

k4= 0.072μM s

E’MTX

-

k-4 =0.0064s
1

Figure 9: Model for the rates of binding and conformational changes associated
with methotrexate binding to the unlabeled Bs DHFR and labeled Bs DHFR.
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Unlabeled DHFR Binding to Methotrexate

Labeled DHFR Binding to Methotrexate
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Figure 10: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of MTX in
MTEN buffer at pH 7 and at 25.7 °C (left). Data File: U MTX Binding No.NADPH
0.25s Data. Data Folder: U MTX Binding No.NADPH. This shows a fast concentration
dependent fluorescence decrease corresponding to the k1 step of rate 23.8 ±2.2 μM- 1s-1.
Labeled Bs DHFR (1 μM) mixed with various concentrations of MTX in MTEN buffer at
pH 7 and at 25.7 °C (right). Data File: L MTX Binding No.NADPH 100s Data. Data
Folder: L MTX Binding No.NADPH. This shows a much slower concentration
dependent fluorescence decrease corresponding to the k4 step of rate 0.072 ±00013 μM1 -1

s . These analyses were done in Dynafit and the script files are located in the Dynafit

Ready Data Files + Scripts folder within each relevant binding folder. These very
different rates at two distinct timescales that are both concentration dependent is what
indicates that there are two separate conformers binding at separate rates. This pattern
was previously determined in prior research by Maryam Alapa [ 1 ]. Maryam Apala’s
research yielded two k1 of 20.2 ±0.21 μM- 1s-1 and 23.99 ±1.9 μM- 1s-1 and a k4 of 0.067
±0.0001 μM- 1s-1. These values are very close matches to my own.
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Unlabeled 0.25s
k1
k-1
Unlabeled 100s
k2
k-2
Labeled 100s
k4
k-4

Standard Error

Average

23.8 μM s
0.8 s-1

2.2
0.29

0.02 s-1
N/A

0.0027
N/A

0.072 μM- 1 s-1
0.0064 s-1

0.00013
0.000066

- 1 -1

Table 2. Rates of binding and conformational changes associated with methotrexate
binding to the unlabeled Bs DHFR and labeled Bs DHFR. Based on Dynafit calculation
of and averaged 3-5 traces per concentration and 3-5 concentrations per rate. Data
Folders: U MTX Binding No.NADPH, L MTX Binding No.NADPH. The script files are
in the Dynafit Ready Data Files + Scripts folder within each relevant binding folder.

Methotrexate binding to Bs DHFR can be modeled as two separate, two step
processes. This implies that Bs DHFR is a dynamic system. Based on this and previous
studies Bs DHFR like many enzymes is not rigid and at equilibrium is most often found
in two forms (E and E’). The separate conformations of Bs DHFR bind methotrexate at
different rates and the motions that Bs DHFR goes through after ligand binding
(E+LE.L and E’+LE’L) can conform to a model where Bs DHFR undergoes a
conformational change after binding takes place (EL  EL’).
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Figure 11: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of MTX in
MTEN buffer at pH 7 and at 25.7 °C (left). Data File: U MTX Binding No.NADPH 100s
Data. Data Folder: U MTX Binding No.NADPH. This shows a slow concentration
independent fluorescence decrease that can be attributed to the k2 step of rate 0.02
±0.0027 s-1 which is a conformational change. Unlabeled Bs DHFR (1 μM) mixed 2.5
μM of MTX in MTEN buffer at pH 7 and at 25.7 °C, control sample was premixed for 5
minutes (right). Data File: U MTX Binding No.NADPH 100s Data +control. Data
Folder: U MTX Binding No.NADPH. The control run is mixed together and allowed to
bind and settle into its conformations before reading its value providing a constant value
with which the conformational change, which can often be subtle, can be more clearly
visualized. The right graph zooms in and shows the conformational change.

NADPH Mixed with Bs DHFR
Determining how NADPH binds to Bs DHFR and what changes in conformation
take place is important for clarifying our understanding of the NADPH/MTX/DHFR
system. Seeing conformational changes in the DHFR.NADPH complex would suggest
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that the conformational equilibrium in DHFR vs. the DHFR.NADPH system are different
and should be treated differently.
The binding of NADPH to unlabeled Bs DHFR causes an NADPH concentration
dependent increase in tryptophan fluorescence (290 nm) intensity. The traces were fitted
to a single step model. This is a fast concentration dependent increase and is over within
0.2 seconds and has a k1 of 19.5 ±0.18 μM- 1 s-1 and a k-1 of 3.9 ±0.11 s-1. (Table 3)

Unlabeled DHFR Binding NADPH
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Figure 12: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of NADPH in
MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U NADPH Binding 0.25s Data.
Data Folder: U NADPH Binding. This shows a fast concentration independent
fluorescence increase that can be attributed to the k1 step of rate 19.5 ±0.18 μM- 1 s-1.
Labeled Bs DHFR (1 μM) mixed with various concentrations of NADPH in MTEN
buffer at pH 7 and at 25.2 °C (right). Data File: L NADPH Binding 0.25s Data. Data
Folder: L NADPH Binding. This shows a fast concentration independent fluorescence
decrease that can be attributed a k4 step of rate 35.6 ±0.11 μM- 1s-1.
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The binding of NADPH to labeled Bs DHFR causes a NADPH concentration
dependent decrease in MDCC fluorescence intensity. The traces were fitted to a single
step equation. This is a fast concentration dependent decrease is over within 0.25 seconds
and has a k4 of 35.6 ±0.15 μM- 1s-1 and a k-4 of near 0 s-1. (Table 3)
Longer unlabeled traces showed a small decrease in fluorescence intensity
indicating a slow NADPH concentration independent decrease. These longer traces were
fit to a two-step model. The fast step is attributed to NADPH binding, k1, and the slower
step is attributed to the conformational change, k2. The rate constant k2 was found to be
0.02 ±0.0002 s-1 and k-2 could not be calculated from the data.
Longer labeled traces showed a small decrease in fluorescence intensity indicating
a slow NADPH independent decrease. These longer traces were fit to a single step model
of a conformational change. The rate constant k-2 was fond to be 0.1 ±0.0041 s-1 and k2
was unable to be calculated from the data. (Table 3)
NADPH binding to Bs DHFR, like methotrexate, can be modeled with two
conformers binding ligand at different rates. It is likely that Bs DHFR existing as two
conformers (E and E’) bind NADPH at different rates and the motions that Bs DHFR
goes through after ligand binding (E+LE.L and E’+LE’L) can conform to a model
where Bs DHFR undergoes a conformational change after binding takes place (EL 
EL’).
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Figure 13: Unlabeled Bs DHFR (1 μM) mixed with various concentrations of NADPH in
MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U NADPH Binding 100s Data.
Data Folder: U NADPH Binding. This shows a slow concentration independent
fluorescence decrease that can be attributed to the k2 step of rate 0.02 ±0.0002 s-1 which is
a conformational change. Unlabeled Bs DHFR (1 μM) mixed with various concentrations
of NADPH in MTEN buffer at pH 7 and at 25.2 °C (right). Data File: L NADPH
Binding 100s Data. Data Folder: L NADPH Binding. This shows a concentration
independent fluorescence decrease that can be attributed to the k-2 step of rate 0.01
±0.0041 s-1 which is a conformational change.
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-1 -1

k1= 19.5μM s
E + NADPH
k3

k-1= 3.9s

ENADPH

-1

k2=0.02s-1

k-3

k-2=0.1s-1

-1 -1

k4= 35.6μM s
E’ + NADPH
k-4 =0s

E’NADPH

-1

Figure 14: Model with the rates of binding and conformational changes associated with
NADPH binding to the unlabeled Bs DHFR and labeled Bs DHFR.

Unlabeled 0.25s
k1
k-1
Unlabeled 100s
k2
Labeled 100s
k-2
Labeled 0.25s
k4
k-4

Standard Error

Rate
-1 -1

19.5μM s
-1
3.9s

0.18
0.11

0.02 s-1

0.0002

0.1 s-1

0.0041

35.6 μM- 1s-1
0 s-1

0.15
0.023

Table 3. Rates of binding and conformational changes associated with methotrexate
binding to the unlabeled Bs DHFR and labeled Bs DHFR. Based on Dynafit calculation
of and averaged 3-5 traces per concentration and 3-5 concentrations per rate. Data
Folders: U NADPH Binding, and L NADPH Binding. The script files are in the Dynafit
Ready Data Files + Scripts folder within each relevant binding folder.
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Methotrexate mixed with DHFR/NADPH Holoenzyme
Finally determining the differences in binding of ligands like methotrexate bind to
the DHFR/NADPH holoenzyme complex can clarify the role of NADPH in Bs DHFR
methotrexate binding and the importance of NADPH to the study and analysis of
inhibitors. A significant change in binding, conformational equilibrium, and/or
dissociation rate would be a clear indication of the importance NADPH being included in
the analysis process.
The binding of methotrexate to unlabeled holoenzyme causes a methotrexate
concentration dependent decrease in tryptophan fluorescence intensity (Fig. 14 left). The
traces were fitted to a single step model. This is a fast concentration dependent increase
and is over within 0.25 seconds and has a k1 of 24.7 ±1.1 μM- 1 s-1 and a k-1 of 0.03 ±0.4 s1

. (Table 4)
The binding of methotrexate to labeled holoenzyme causes a methotrexate

concentration dependent decrease in MDCC fluorescence intensity (Fig. 14 right). The
traces were fitted to a single step equation. This is a much slower concentration
dependent decrease and is over within 100 seconds and has a k4 of 0.052 ±0.024 μM- 1s-1
and a k-4 of 0.03 ±0.01 s-1. (Table 4)
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Figure 15: Unlabeled Bs DHFR (1 μM) premixed with NADPH (5 μM) and then mixed
with various concentrations of MTX in MTEN buffer at pH 7 and at 25.7 °C (left). Data
File: U MTX Binding W.NADPH 0.25s Data. Data Folder: U MTX Binding
W.NADPH. This shows a fast concentration dependent fluorescence decrease
corresponding to the k1 step of rate 24.7 ±1.1 μM-

1

s-1. Labeled Bs DHFR (1 μM)

premixed with NADPH (5 μM) and then mixed with various concentrations of MTX in
MTEN buffer at pH 7 and at 25.7 °C (right). Data File: L MTX Binding W.NADPH
100s Data. Data Folder: L MTX Binding W.NADPH This shows a much slower
concentration dependent fluorescence decrease corresponding to the k4 step of rate 0.052
±0.024 μM- 1s-1.
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k1= 24.7μM s
ENADPH + MTX

ENADPHMTX

-1

k3

k-3

k-1= 0.03s
-1
k2=0.054 s

k-2=N/A

-1 -1

k4= 0.052μM s
ENADPH’MTX
ENADPH’ + MTX
k-4 =0.03s

-1

Figure 16: Model for the rates of binding and conformational changes associated with
methotrexate binding to the unlabeled DHFR.NADPH complex and labeled
DHFR.NADPH complex.

Unlabeled 0.25s
k1
k-1
Unlabeled 100s
k2
k-2
Labeled 100s
k4
k-4

Standard Error

Average

24.7 μM s
0.03 s-1

1.1
0.4

0.054 s-1
N/A

0.0019
N/A

0.052 μM- 1s-1
0.03 s-1

0.024
0.01

- 1 -1

Table 4. Rates of binding and conformational changes associated with methotrexate
binding to the unlabeled DHFR.NADPH complex and labeled Bs DHFR.NADPH
complex. Based on Dynafit calculation of and averaged 3-5 traces per concentration and
3-5 concentrations per rate. Data Folders: U MTX Binding W.NADPH, L MTX Binding
W.NADPH. The script files are in the Dynafit Ready Data Files + Scripts folder within
each relevant binding folder.
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Dissociation rates of methotrexate from Bs DHFR and the DHFR.NADPH complex
Determining the differences in the dissociation of ligands like methotrexate from
Bs DHFR and the DHFR.NADPH complex can clarify the role of NADPH in Bs DHFR
methotrexate binding and the importance of NADPH to the study and analysis of
inhibitors. A significant change in dissociation, indicates an importance of the cofactor in
not just activating the enzyme but preventing ligands from dissociating.
The dissociation of methotrexate from unlabeled Bs DHFR causes a decrease in
tryptophan fluorescence intensity (Fig. 16 left). The rates were calculated an exponential
decay model. This shows a fluorescence decrease corresponding to the dissociation rate
of 0.015 s-1 ±0.007965.
The dissociation of methotrexate from labeled Bs DHFR causes an increase in
tryptophan fluorescence intensity (Fig. 16 right). The rates were calculated an
exponential rise model. This shows a fluorescence increase corresponding to the
dissociation rate of 0.02 s-1 ±0.0000921.
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Figure 17: Unlabeled Bs DHFR (1 μM) premixed with methotrexate (5 μM) mixed with
trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U
MTX Dissociation No NADPH Data. Data Folder: U MTX Dissociation No.NADPH.
This shows a fluorescence decrease corresponding to the dissociation rate of 0.015 s-1
±0.007965. Labeled Bs DHFR (1 μM) premixed with methotrexate (5 μM) and then
mixed with trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (right).
Data File: L MTX Dissociation No NADPH Data. Data Folder: L MTX Dissociation
No.NADPH. This shows a fluorescence increase corresponding to the dissociation rate of
0.02 s-1 ±0.0000921.

The dissociation of methotrexate from the unlabeled DHFR.NADPH complex
causes a decrease in tryptophan fluorescence intensity (Fig. 17 left). The rates were
calculated an exponential decay model. This shows a fluorescence decrease
corresponding to the dissociation rate of 2.87e-5 s-1 ±0.82 e-5.
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Figure 18: Unlabeled Bs DHFR (1 μM) premixed with methotrexate (5 μM) mixed with
trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and at 25.2 °C (left). Data File: U
MTX Dissociation With NADPH Data. Data Folder: U MTX Dissociation W.NADPH.
This shows a fluorescence decrease corresponding to the dissociation rate of 2.87e-5 s-1
±0.82 e-5. Labeled Bs DHFR (1 μM) premixed with methotrexate (5 μM), and NADPH
(5 μM), and then mixed with trimethoprim (TMP 700 μM) in MTEN buffer at pH 7 and
at 25.2 °C (right). Data File: Labeled MTX Dissociation With NADPH Data. Data
Folder: L MTX Dissociation W.NADPH. This shows a fluorescence increase
corresponding to the dissociation rate of 2.1e-5 s-1 ±0.271 e-5. This specific dissociation
curve for the labeled enzyme had irregularities that appeared in the control experiment.
(run 48 hours without NADPH) The control was used in file L MTX Dissociation
W.NADPH and was subtracted from the average dissociation curve to correct for the
irregularities.
The dissociation of methotrexate from the labeled DHFR.NADPH complex
causes an increase in tryptophan fluorescence intensity (Fig. 17 right). The rates were

31

calculated an exponential rise model. This shows a fluorescence increase corresponding
to the dissociation rate of 2.1e-5 s-1 ±0.271 e-5.
Discussion
Previously determined experimental results were verified by our experiments and
the kinetic data is consistent with previously determined models for methotrexate
binding. We confirmed that Bs DHFR exists in two distinct configurations E and E’ at a
ratio of 0.7:0.3. We have extended scope of the model to include the cofactor NADPH
binding resulting in a ENADPH and E’NADPH ratio of 0.6:0.4. This multistep model is
supported by the distinct NADPH and methotrexate binding rates calculated from
tryptophan fluorescence and the MDCC fluorophore fluorescence. Furthermore, the
model is valid when methotrexate binding to the holoenzyme is determined following
NADPH bindings.
The difference in rate of methotrexate binding between the apoenzyme and the
holoenzyme is indicative of the importance of the cofactor. However, the most significant
change from the binding of Bs DHFR to NADPH is that the dissociation rate of
methotrexate from the bound complex is reduced. This shift results in an increase in
stability. This makes sense from a biological perspective as it ensures that when all
components are present in solution that they not only bind to each other at an appropriate
speed but also that they remain bound so that they achieve an appropriate reaction rate.
The scale of the shift in dissociation rate is very interesting. The dissociation rate of the
Bs DHFR without cofactor is fast while with cofactor it is 1000 times slower, a drastic
decrease (Fig. 18).
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Figure 19: Labeled methotrexate dissociation without NADPH (Fig. 16 right) compared
to with NADPH (Fig. 17 right). Here we can clearly visualize the difference in timescale
caused by NADPH. When there is no NADPH the timescale for dissociation is 600
seconds with a rate of 0.02 s-1 ±0.0000921 and when there is NADPH the timescale for
dissociation is 48 hours with a rate of 2.1e-5 s-1 ±0.271 e-5.

We can conclude that important information regarding the kinetics of enzymes
and of Bs DHFR in particular are missing if the analysis of inhibitor binding data is
preformed while a key cofactor is missing. This is especially true when analyzing
pharmaceuticals. For example, a cell with high energy (high NADPH concentration)
would remain inhibited by methotrexate for much longer than a cell with low energy.
This difference could alter effectiveness and toxicity so should be carefully analyzed.
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Appendix

𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆
= 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏(𝑴)
𝑬𝒙𝒕𝒊𝒏𝒄𝒕𝒊𝒐𝒏 𝒄𝒐𝒆𝒇𝒇𝒊𝒄𝒆𝒏𝒕 (𝑴−𝟏 𝒄𝒎−𝟏 ) ∗ 𝑷𝒂𝒕𝒉 𝒍𝒆𝒏𝒈𝒕𝒉 (𝒄𝒎)

𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟒𝟏𝟗 𝒏𝒎)
𝑬𝒙𝒕. 𝒄𝒐𝒆𝒇𝒇, (𝟓𝟎𝟎𝟎𝟎𝑴−𝟏 𝒄𝒎−𝟏 ) ∗ 𝑷𝒂𝒕𝒉 𝒍𝒆𝒏𝒈𝒕𝒉 (𝟎. 𝟏𝒄𝒎)
= 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴)

𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴) ∗ 𝑬𝒙𝒕. 𝒄𝒐𝒆𝒇𝒇, (𝟏𝟎𝟎𝟎𝟎𝑴−𝟏 𝒄𝒎−𝟏 )
∗ 𝑷𝒂𝒕𝒉 𝒍𝒆𝒏𝒈𝒕𝒉 (𝟎. 𝟏𝒄𝒎) = 𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎)

𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑻𝒐𝒕𝒂𝒍 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎) − 𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎)
= 𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑼 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎)

𝑨𝒃𝒔𝒐𝒓𝒃𝒂𝒏𝒄𝒆 𝑼 𝑬𝒏𝒛𝒚𝒎𝒆 (𝟐𝟖𝟎 𝒏𝒎)
𝑬𝒙𝒕. 𝒄𝒐𝒆𝒇𝒇, (𝟐𝟓𝟓𝟔𝟓𝑴−𝟏 𝒄𝒎−𝟏 ) ∗ 𝑷𝒂𝒕𝒉 𝒍𝒆𝒏𝒈𝒕𝒉 (𝟎. 𝟏𝒄𝒎)
= 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑼 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴)

𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴)
𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑼 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴) + 𝑪𝒐𝒏𝒄𝒆𝒏𝒕𝒓𝒂𝒕𝒊𝒐𝒏 𝑳 𝑬𝒏𝒛𝒚𝒎𝒆(𝑴)
= 𝑳𝒂𝒃𝒆𝒍𝒊𝒏𝒈 𝑬𝒇𝒇𝒊𝒄𝒊𝒆𝒏𝒄𝒚

Figure 20: Equation for converting absorbance to concentration and for measuring
labeling efficiency. Absorbance of labeled enzyme at 419 nm and of total enzyme at 280
nm are the measured values for calculating labeling efficiency.
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Figure 21: Sample calculation sheet of absorbance, needed label concentration, and
labeling efficiency using the equations laid out in Fig. 19 File: Absorbance Calculation
(In the base data folder). Bold values are measured values and the file auto calculates
everything else.
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Inventory
Box 1 DHFR supplies
A.
B.
C.
D.
E.
F.
G.
H.
I.
J.
K.

2x 0.5mL tube MTX 35.4mM
1x 1.5mL tube MTX 1000uM
1x 1.5mL tube NADPH 1000uM
1x 0.5mL tube TMP 365mM
1x 1.5mL tubes of labeled enzyme
4x 0.5mL tubes of Labeled enzyme 47.29uM
1x 1.5mL tube of transformed E. coli cell culture C73A, S131C
3x1.5mL tubes of unlabeled enzyme
1x 1.5mL tube MDCC old Stock
2x 0.5mL tube of MDCC at 0.22mg/mL
4x 0.5mL tube of unknown (variable) concentration of MDCC (contain
particulate)

(box #2 was combined into box 1)

A

F

B

D
G

H
E

J

I
C

K
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Box #3 DHFR pellets
A. 2x Falcon tubes each contain a cell pellet
B. 1x 10 mL tube with DHFR

B

A

Box 4 Maryam Legacy box
A. Old Pellets from 2012
B. 1x 1.5mL tube of transformed E. coli cell culture C73A, S131C

B

A
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Box 1, 3, 4 in the stand

The stand (A) in the Freezer

1

2

A

3
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